Microfluidic iPSC Workflow for Automated Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing induced pluripotent stem cells (iPSCs) are time-consuming and labor-intensive, and there is a need for improved microfluidic devices and methods to automate the processing of patient-specific cells for therapeutic applications, addressing ethical concerns and inefficiencies in cell differentiation and reprogramming.
Innovation Solution
A microfluidic system that integrates sample processing, cell isolation, expansion, reprogramming, and differentiation, utilizing computer-controlled microfluidic units and modified RNAs to generate patient-specific reprogrammed cells efficiently and reproducibly, enabling automated workflows for generating iPSCs and differentiated cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If manual methods are used for cell isolation, expansion, and reprogramming, then flexibility and adaptability are maintained, but time consumption and labor intensity increase significantly
Solution Approach 1:
The microfluidic device divides the cell processing workflow into distinct modular chambers: isolation chamber for cell separation, expansion chamber for cell proliferation, and reprogramming chamber for iPSC generation. Each chamber performs a specific function, enabling automated sequential processing that eliminates manual intervention while maintaining process flexibility through modular design.
Solution Approach 2:
Manual mechanical operations (pipetting, cell counting, media changes) are replaced by an automated control system that regulates fluid flow through the microfluidic channels. The system uses electronic control to manage cell processing steps, replacing labor-intensive mechanical operations with automated fluid handling and electronic monitoring.
2Manufacturing precision
If complex microfluidic control machinery is integrated into the chip, then precise transfer and mixing are achieved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The microfluidic device integrates multiple functions into a single chip platform: cell isolation, expansion, reprogramming, and differentiation capabilities. This multi-functional design achieves precise cell manipulation without requiring separate complex control systems for each operation, as the unified microfluidic architecture handles diverse tasks through integrated channel networks and chambers.
Solution Approach 2:
The device merges cell processing functions that were traditionally performed in separate laboratory equipment into a single microfluidic chip. The isolation, expansion, and reprogramming chambers are combined in one integrated device, eliminating the need for multiple separate control systems and reducing overall device complexity while maintaining precise manufacturing control.
3Adaptability or versatility
If embryonic stem cells are used for therapeutic applications, then pluripotency and differentiation potential are maximized, but ethical concerns and availability limitations arise
Solution Approach 1:
The microfluidic device uses somatic cells (adult cells) as an intermediary source instead of directly using embryonic stem cells. These somatic cells are reprogrammed within the device to generate induced pluripotent stem cells (iPSCs) that possess differentiation potential similar to embryonic stem cells, thereby avoiding ethical issues related to embryo destruction while maintaining therapeutic versatility.
Solution Approach 2:
The device changes the biological state of somatic cells through reprogramming, transforming them from a differentiated state back to a pluripotent state. This parameter change in cellular potency enables the use of ethically acceptable cell sources while achieving the desired differentiation potential for therapeutic applications.
Data Source
AI summary
This invention concerns an integrated microfluidic system that utilizes microfluidic chip technology to receive a patient sample including cells, expand the cells, reprogram the expanded cells and then store the reprogrammed cells in a microfluidic chip. These microfluidic chips with stored reprogrammed cells may then be used in scenarios of genetic differentiation into specific cell types. Overall this system and workflow is suitable as a hospital based device that will allow the generation of iPSCs from every patient for downstream diagnostic or therapeutic use.